

CORRECTION

Open Access



Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a

Man-Qing Cao^{1,2}, A-Bin You³, Xiao-Dong Zhu¹, Wei Zhang², Yuan-Yuan Zhang¹, Shi-Zhe Zhang¹, Kei-wei Zhang⁴, Hao Cai¹, Wen-Kai Shi¹, Xiao-Long Li¹, Kang-Shuai Li¹, Dong-Mei Gao¹, De-Ning Ma⁵, Bo-Gen Ye⁶, Cheng-Hao Wang⁷, Cheng-Dong Qin⁸, Hui-Chan Sun^{1*}, Ti Zhang^{2*} and Zhao-You Tang^{1*}

The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK.

As such, the correct version of Fig. 5a with the correct representation of the Western blots of SGK can be seen ahead.

Author details

¹Department of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.

²Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. ³Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, Haidian District, Beijing 100142, China. ⁴Department of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.

⁵Department of Colorectal Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China. ⁶Department of Organ Transplantation, Changshai Hospital, The Second Military Medical University, Shanghai 200433, China. ⁷Department of Liver Surgery, Fudan University Shanghai Cancer Center, Cancer Hospital, Shanghai 200032, China. ⁸Department of Breast Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China.

Received: 4 April 2018 Accepted: 6 April 2018

Published online: 18 April 2018

Reference

1. Cao M-Q, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. *J Hematol Oncol.* 2018;11:12.

* Correspondence: sun.huichuan@zs-hospital.sh.cn; zhangti@tjmuch.com; zytang88@163.com

¹Department of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China

²Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

